CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-20 | Satvat Ali J. Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | MOMTAZEE JAMES C Director | Grant or award | +6,589 | 95,080 | ||
| 2025-06-20 | MOMTAZEE JAMES C Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | HOMCY CHARLES J Director | Grant or award | +6,589 | 1,236,674 | ||
| 2025-06-20 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | Hassan Fred Director | Grant or award | +6,589 | 25,889 | ||
| 2025-06-20 | Hassan Fred Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | Dachille Douglas A. Director | Grant or award | +6,589 | 6,589 | ||
| 2025-06-20 | Dachille Douglas A. Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | Valantine Hannah Director | Grant or award | +6,589 | 8,353 | ||
| 2025-06-20 | Valantine Hannah Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-20 | Scott Randal W. Director | Grant or award | +6,589 | 11,589 | ||
| 2025-06-20 | Scott Randal W. Director | Grant or award · Stock Option (Right to Buy) | +8,425 | 8,425 | ||
| 2025-06-10 | Valantine Hannah Director | Option exercise 10b5-1 | +4,292 | $16.75 | $72K | 6,056 |
| 2025-06-10 | Valantine Hannah Director | Sale 10b5-1 | −4,292 | $40.00 | $172K | 1,764 |
| 2025-06-10 | Valantine Hannah Director | Option exercise · Stock Option (right to buy) 10b5-1 | −4,292 | 34,334 | ||
| 2025-05-20 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −75,000 | $33.40 | $2.5M | 4,798,447 |
| 2025-05-19 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −25,756 | $33.32 | $858K | 217,804 |
| 2025-05-19 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −400 | $33.75 | $13K | 217,404 |
| 2025-05-16 | Kumar Neil Chief Executive Officer | Option exercise 10b5-1 | +64,696 | 276,414 |
Page 18 of 19 · 379 trades